Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

October 31, 2018

Conditions
Actinic Keratosis
Interventions
DRUG

Vehicle gel

placebo

DRUG

SR-T100 with 2.3% of SM

2.3% of SM in Solanum undatum plant extract

Trial Locations (8)

24501

The Education & Research Foundation, Inc, Lynchburg

33406

Atlantic Clinical Research Collaborative, West Palm Beach

33409

Palm Beach Research Center, West Palm Beach

77056

Suzanne Bruce and Associates,P.A. The Center for Skin Research, Katy

78660

Pflugerville Dermatology Clinical Research, Pflugerville

80501

IMMUNOe International Research Centers, Longmont

92270

Contour Dermatology & Cosmetic Surgery Center, Rancho Mirage

99204

Premier Clinical Research, Spokane

All Listed Sponsors
lead

G&E Herbal Biotechnology Co., LTD

INDUSTRY

NCT01516515 - Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis | Biotech Hunter | Biotech Hunter